|Source||Humanized (from mouse)|
|Biological half-life||20 days|
|CAS Registry Number|
|(what is this?)|
Mepolizumab is a humanized monoclonal antibody that recognizes interleukin-5 (IL-5). Mepolizumab has been investigated or is under investigation for the treatment of severe eosinophilic asthma, atopic dermatitis, hypereosinophilic syndrome (HES), eosinophilic esophagitis (EoE), nasal polyposis, eosinophilic granulomatosis with polyangiitis (EGPA) (i.e., Churg Strauss syndrome), and chronic obstructive pulmonary disease (COPD). Phase III clinical trials in severe eosinophilic asthma were completed in 2014.